Marina Picillo1,2,3, Karlo J Lizarraga2,3, Erik L Friesen4, Hien Chau4, Ming Zhang5, Christine Sato5, Grace Rooke5, Renato P Munhoz2,3, Ekaterina Rogaeva3,5, Paul E Fraser5,6, Suneil K Kalia4,7, Lorraine V Kalia2,3,4,5. 1. Center for Neurodegenerative Diseases (CEMAND), Department of Medicine and Surgery, University of Salerno, Salerno, Italy. 2. Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Division of Neurology, Department of Medicine, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada. 3. Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 4. Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada. 5. Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada. 6. Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. 7. Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND: SNCA mutations cause autosomal dominant parkinsonism and inform our understanding of the molecular underpinnings of synucleinopathies. The most recently identified mutation, p.Ala53Glu (A53E), has only been observed in Finland. The objectives of this study were to examine clinical, genetic, epigenetic, and biochemical features of the first family outside Finland with A53E. METHODS: We examined a Canadian family with parkinsonism because of A53E using haplotype and DNA methylation analyses. We assessed aggregation properties of A53E α-synuclein in vitro. RESULTS: Family members with parkinsonism shared a common haplotype distinct from Finnish patients with A53E. Increased acceleration of DNA methylation age was accompanied by earlier age at onset in the family members. We demonstrate that A53E α-synuclein has a propensity to form oligomers and phosphorylation promotes fibrillation. CONCLUSIONS: A53E as a cause of parkinsonism is not restricted to Finnish individuals. DNA methylation may contribute to disease age at onset. A53E enriches α-synuclein oligomers and fibrils dependent on the phosphorylation state.
BACKGROUND:SNCA mutations cause autosomal dominant parkinsonism and inform our understanding of the molecular underpinnings of synucleinopathies. The most recently identified mutation, p.Ala53Glu (A53E), has only been observed in Finland. The objectives of this study were to examine clinical, genetic, epigenetic, and biochemical features of the first family outside Finland with A53E. METHODS: We examined a Canadian family with parkinsonism because of A53E using haplotype and DNA methylation analyses. We assessed aggregation properties of A53E α-synuclein in vitro. RESULTS: Family members with parkinsonism shared a common haplotype distinct from Finnish patients with A53E. Increased acceleration of DNA methylation age was accompanied by earlier age at onset in the family members. We demonstrate that A53E α-synuclein has a propensity to form oligomers and phosphorylation promotes fibrillation. CONCLUSIONS:A53E as a cause of parkinsonism is not restricted to Finnish individuals. DNA methylation may contribute to disease age at onset. A53E enriches α-synuclein oligomers and fibrils dependent on the phosphorylation state.
Authors: Ming Zhang; Allison A Dilliott; Roaa Khallaf; John F Robinson; Robert A Hegele; Michael Comishen; Christine Sato; Giuseppe Tosto; Christiane Reitz; Richard Mayeux; Peter St George-Hyslop; Morris Freedman; Ekaterina Rogaeva Journal: Brain Date: 2019-11-01 Impact factor: 13.501
Authors: Eduardo P De Mattos; Anne Wentink; Carmen Nussbaum-Krammer; Christian Hansen; Steven Bergink; Ronald Melki; Harm H Kampinga Journal: J Parkinsons Dis Date: 2020 Impact factor: 5.568